Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
POM121 transmembrane nucleoporin-like 12 (POM121L12) is a member of the nucleoporin family, classified as a transmembrane glycoprotein and a predicted structural component of the nuclear pore complex (NPC)[2][4][6]. It shares similarity with the canonical POM121 protein, which is an essential membrane-anchored nucleoporin necessary for the assembly and function of NPCs, mediating regulated transport between the nucleus and cytoplasm[4][6]. The specific biological functions and disease associations of POM121L12 remain largely uncharacterized, but gene ontology annotations indicate it likely contributes structurally to the NPC[4]. No validated roles as a therapeutic target, nor evidence for interacting drugs, biomarker utility, or specific safety concerns, have been described for POM121L12[2][4][6][8]. While perturbations in POM121L12 gene expression have been noted across diverse datasets, this reflects general functional association data and does not suggest a defined therapeutic application[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on POM121 transmembrane nucleoporin-like 12 (POM121L12).